The document announces the 2017 Annual Meeting to take place October 25-26, 2017 in Boston, Massachusetts. It will feature opportunities in personalized medicine with speakers from Digital Science, TriLink Biotechnologies, and New England Biolabs. There are also links to YouTube videos about the annual meeting from July 2017. The document discusses funding trends for CAR T-cell and CRISPR research over time, with international funders like Germany, the EU, and China playing a growing role in recent years building upon the foundational work by Dr. Carl June and the NCI in the early 2000s. Current funding and publication trends indicate CAR research remains small compared to leukemia research overall, while new interest in CRISPR provides more
2. 2017 Annual Meeting
Opportunities in Personalized Medicine
Aaron Sorensen, Digital Science with
Craig Dobbs, TriLink Biotechnologies
Andy Bertera, New England Biolabs
5. 2017 Annual Meeting
How was Carl June’s
collaborator ecosystem
funded since 2001 when
he first began treating
patients? Which funders
contributed most to the
scientific impact of those
translational years?
-- International funders
not playing much of a
role, and a couple US
foundations “punching
above their weight.”
6. 2017 Annual Meeting
Top 5 funders from previous slide
broken up by papers published each
year to show a given funder’s
importance can ebb and flow over
time. E.g., Novartis has become
huge in recent years
7. 2017 Annual Meeting
2010 marks the
beginning of the T-CAR
clinical trials. In these
recent years, when June
has published his results
and credits previous
work (both his and
others’), which funders
were most responsible
for allowing him to
“stand on the shoulders
of giants”?
-- International funders
playing a bigger role with
Germany and the EU
creeping into the Top 10.
8. 2017 Annual Meeting
Top 5 funders from previous slide broken
up by papers published each year to
show a given funder’s importance can
ebb and flow over time. E.g., in the early
going it was mostly the NCI funding the
seminal work.
9. 2017 Annual Meeting
In the years since 2010
scientists from all over
the world have been
working to replicate and
build upon June’s
breakthrough. Who is
funding these recent
studies which build upon
June’s work of the last
seven years?
-- Big growth in
international funding
with Germany, the EU,
and now China in the Top
5.
10. 2017 Annual Meeting
Top 5 funders from
previous slide broken up
by papers published
each year to show a
given funder’s
importance can ebb and
flow over time. E.g.,
China is on an incredible
growth trajectory
11. 2017 Annual Meeting
Current Funding &
Publication trends for
CAR & CRISPR.
CAR is still a drop in the
bucket of Leukemia
research.
The term, “CRISPR,” is
new enough that there is
a lot of funding available
but not yet the resulting
papers.